234 results
Page 5 of 12
6-K
EX-99.1
krn2 8jspao08q
2 Jun 14
Appoints Sigurdur Olafsson As President and Ceo of Newly Established Global Generic Medicines Group
12:00am
6-K
EX-99.1
wax6ug1 fl
3 Mar 14
The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
12:00am
6-K
EX-99.1
ves8n6
21 Feb 14
Live Filing
12:00am
6-K
EX-99.1
ryuq1eypdgjmfcb3
9 Jan 14
Teva Names Erez Vigodman as President and CEO
12:00am
6-K
EX-99.1
50x0 o5f88t
10 Dec 13
Teva Provides 2014 Non-GAAP Financial Outlook
12:00am
6-K
EX-99.1
c1wxqoldr8cq xqmt
4 Dec 13
Live Filing
12:00am
6-K
EX-99.1
lk3pf soj
19 Nov 13
Live Filing
12:00am
6-K
jyfwa05rnbgrbke3
31 Oct 13
Current report (foreign)
12:00am
6-K
EX-99.1
pmzl04 23
31 Oct 13
Teva Reports Third Quarter 2013 Results
12:00am
6-K
EX-99.1
y30f2gy35j1d9ktc
30 Oct 13
Teva Announces Departure of President and Ceo
12:00am
6-K
EX-99.1
rvndp3nvkf2
9 Oct 13
Teva R&D in Focus - Respiratory Webinar for the investment communityOctober 8th, 2013
12:00am
6-K
EX-99.1
83kvar9uu97yz
30 Sep 13
Live Filing
12:00am
6-K
EX-99.1
0t6vbxp3l9ekujgq7
25 Jul 13
Teva and Lonza Announce Mutual Decision to Discontinue Biologics Joint Venture
12:00am
6-K
f8e1q0wuuk hoplej
18 Jul 13
Current report (foreign)
12:00am
6-K
EX-99.1
zp0aa2tl 74x
8 May 13
Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder
12:00am
6-K
qk82m1hf 9w
2 May 13
Current report (foreign)
12:00am
6-K
EX-99.1
31s2si5tqwhek sq1shx
2 May 13
Teva Reports First Quarter 2013 Results
12:00am
6-K
EX-99.1
5y7grb8xpv5k vbs
29 Apr 13
Live Filing
12:00am
6-K
546f018l
29 Apr 13
Live Filing
12:00am